KPTI - Karyopharm's XPOVIO now available in additional strength tablets

Karyopharm Therapeutics ([[KPTI]] -1.2%) announces that three new strength tablets for XPOVIO, the company's oral Selective Inhibitor of Nuclear Export ((SINE)) medicine, are now commercially available.The availability of these additional strength tablets follows a U.S. FDA approval in April.The U.S. health regulator had approved XPOVIO in combination with bortezomib and dexamethasone for patients with multiple myeloma after at least one prior therapy, in December last year.

For further details see:

Karyopharm's XPOVIO now available in additional strength tablets